Apex Medical Corp, a $75-million company in Taiwan is initially investing 100 crore in Indian healthcare market which the company believes it is the right time to invest in India. The reason for choosing India as its first country was given by Daniel Lee, CEO, Apex Medcial Corp who said “Why we chose India as the first country in South Asia for our foray is because it has a huge population and a new government that is willing to make a big change.” 100 per cent FDI for Medical Devices proves the willing to change.
READ ALSO: Why Invest in India?, Assessment of Indian Market.
The Indian Healthcare Market is growing at 12 – 15 per cent a year and the Make in India campaign by the new government under Prime Minister Narendra Modi is catching the eye of all medical manufacturers so as Apex Medical Corp. They will market quality and affordable equipment and launch their products in the field of respiratory therapy, such as asthma and sleep apnea and said they were excited about the Indian market.
READ ALSO: Stunning First Visit PM Modi in the US: What it means to the Life Science Sector
Regarding the company’s plans to manufacture in India, Daniel said, “we will start to initially bring from Taiwan and once we know how Make in India takes off we will make it here”. “On research and development we are investing 5 per cent of annual revenue and the products are distributed to US, Europe and other markets through subsidiaries and partners.” he added.
Other News
Imports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read MoreErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read MoreTUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read MoreTGA Supports MHRA’s New Regulations
The TGA made a commitment to support the MHRA‘s new Regulations worldwide recognition framework for pharmaceuticals. Following the UK’s exit from the European Union, a new international recognition framework for medicines has been developed specifically […]
Read More